Mark Sullivan Sells 13,008 Shares of Definium Therapeutics (NASDAQ:DFTX) Stock

Definium Therapeutics, Inc. (NASDAQ:DFTX) insider Mark Sullivan sold 13,008 shares of Definium Therapeutics stock in a transaction dated Thursday, June 25th. The shares were sold at an average price of $45.03, for a total value of $585,750.24. Following the completion of the transaction, the insider directly owned 320,571 shares of the company’s stock, valued at $14,435,312.13. This represents a 3.90% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Definium Therapeutics Price Performance

NASDAQ:DFTX traded up $0.16 during mid-day trading on Friday, reaching $44.95. 12,203,314 shares of the company were exchanged, compared to its average volume of 2,289,586. Definium Therapeutics, Inc. has a 12 month low of $6.40 and a 12 month high of $47.01. The company has a fifty day moving average of $24.13 and a 200 day moving average of $19.18. The company has a quick ratio of 4.69, a current ratio of 4.69 and a debt-to-equity ratio of 0.15. The stock has a market cap of $4.48 billion, a PE ratio of -18.05 and a beta of 2.37.

Definium Therapeutics (NASDAQ:DFTX) last announced its earnings results on Friday, May 8th. The company reported ($0.71) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.23). On average, research analysts anticipate that Definium Therapeutics, Inc. will post -2.29 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in DFTX. Royal Bank of Canada increased its holdings in Definium Therapeutics by 10.4% in the first quarter. Royal Bank of Canada now owns 65,237 shares of the company’s stock valued at $382,000 after purchasing an additional 6,148 shares during the last quarter. Creative Planning increased its stake in shares of Definium Therapeutics by 2.6% in the 2nd quarter. Creative Planning now owns 66,097 shares of the company’s stock valued at $429,000 after acquiring an additional 1,655 shares during the last quarter. JPMorgan Chase & Co. raised its position in shares of Definium Therapeutics by 5.1% in the 2nd quarter. JPMorgan Chase & Co. now owns 48,487 shares of the company’s stock valued at $315,000 after acquiring an additional 2,342 shares during the period. Rhumbline Advisers raised its position in shares of Definium Therapeutics by 6.3% in the 2nd quarter. Rhumbline Advisers now owns 115,296 shares of the company’s stock valued at $748,000 after acquiring an additional 6,839 shares during the period. Finally, Russell Investments Group Ltd. boosted its stake in Definium Therapeutics by 110.4% during the 2nd quarter. Russell Investments Group Ltd. now owns 3,817 shares of the company’s stock worth $25,000 after acquiring an additional 2,003 shares during the last quarter. 27.91% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several research analysts have issued reports on the company. Stifel Nicolaus set a $30.00 price objective on Definium Therapeutics and gave the stock a “buy” rating in a report on Thursday, April 16th. HC Wainwright upped their price target on Definium Therapeutics from $55.00 to $70.00 and gave the company a “buy” rating in a research note on Monday, March 2nd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Definium Therapeutics in a research report on Tuesday, April 21st. Canaccord Genuity Group set a $60.00 price objective on Definium Therapeutics in a report on Monday. Finally, JonesTrading upped their target price on shares of Definium Therapeutics from $61.00 to $74.00 and gave the company a “buy” rating in a research report on Wednesday. Two analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $47.08.

About Definium Therapeutics

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.